Skip to main content
. 2021 Dec 26;2021:1894155. doi: 10.1155/2021/1894155

Table 2.

Comparison of patients eligible for DAPA-HF compared to ineligible patient according to exclusion criteria.

Characteristic Patients eligible for DAPA-HF (n = 352) Patients not eligible due to NT-proBNP below threshold (n = 203) Patient not eligible due to eGFR < 30 ml/min/m2 (n = 84)
p value p value
Age-yr 79 (±10.0) 70.9 (±12.3) <0.001 84.0 (±8.0) <.001
Female sex-no. (%) 119 (33.8) 52 (23.6 0.02 33 (39.3) 0.41
Body mass index-kg/m2 26.4 (±4.9) 28.7∗∗ (±5.0) <0.001 27.3∗∗∗ (±4.9) 0.13
Heart rate- beats/min 75.6 (±17.3) 71.3 (±13.9) 0.002 76.7 (±15.3) 0.2
Systolic blood pressure-mmHg 124 (±18.2) 125 (±16.8) 0.2 128 (±19.5) 0.6
Left ventricle ejection fraction-% 32.4 (±6.8) 34.8 (±5.6) <0.001 32.9 (±6.5) 0.59
Median NT-proBNP-Pg/ml (IQR) 1943 (1138-3562) 286 (164-476) 3409.5 (1785-7073.75)
eGFR-ml/min/1.73 m2 54.4 (±15.0) 65.5 (±17.8) <0.001 21.5 (±5.9) <0.001
Rate of eGFR <60 ml/min/1.73 m2-no./total no. (%) 239/352 (67.9) 75/203 (36.9) <0.001 84/84 (100)
Hospitalization for heart failure-no. (%) 182 (51.7) 102 (47.8) 0.42 39 (58.2) 0.2
Atrial fibrillation-no. (%) 198 (56.3) 65 (32.0) <0.001 46 (54.8) 0.9
Diabetes mellitus-No. (%) 74 (21.0) 58 (28.6) 0.06 35 (41.7) <.001
Hypertension-no. (%) 222 (63.1) 137 (67.4) 0.34 69 (82.1) .001
Ischemic etiology-no. (%) 163 (46.3) 106 (48.2) 0.52 41 (48.8) 0.77
Heart failure treatment
ACE-inhibitor or ARB-no. (%) 258 (73.3) 151 (74.4) 0.86 68 (81.0) 0.19
ARNI-no. (%) 63 (17.9) 45 (22.5) 0.27 4 (4.8) 0.005
Beta blocker-no. (%) 322 (91.5) 192 (94.6) 0.24 78 (92.9) 0.8
MRA-no. (%) 213 (60.6) 136 (67.0) 0.15 35 (41.7) 0.003
Loop diuretics-no. (%) 233 (66.2) 96 (47.3) <.001 76 (90.5) <.001
Digitalis-no. (%) 56 (15.9) 26 (12.8) 0.39 13 (15.5) 1
ICD-no. (%) 47 (13.4) 52 (25.6) <.001 6 (7.1) 0.17
CRT-no. (%) 53 (15.1) 37 (18.2) 0.39 12 (14.3) 0.9

Number in parentheses is ±1 standard deviation; eGFR: estimated glomerular filtration rate; NT-proBNP: N-terminal pro-B-type natriuretic peptide; ACE: angiotensin converting enzyme; ARB: angiotensin receptor blocker; ARNI: angiotensin receptor blocker and neprilysin inhibitor; MRA: mineral corticoid antagonist; ICD: implantable cardioverter-defibrillator; CRT: cardiac resynchronization therapy. p values are in relation to the eligible patients. BMI available for 333/352 patients. ∗∗BMI available for 197/203 patients. ∗∗∗BMI available for 82/84 patients.